慢性阻塞性肺疾病急性加重期血清淀粉样蛋白A水平变化及其临床意义
|
摘要
目的探讨慢性阻塞性肺疾病急性加重期血清淀粉样蛋白A水平变化及其临床意义。方法选择2016年9月-2017年9月住院的慢性阻塞性肺疾病急性加重期患者80例为观察组,另取同期健康体检者80例为对照组,对2组血清淀粉样蛋白A水平进行检测,比较慢性阻塞性肺疾病急性加重期患者不同程度血清淀粉样蛋白A水平变化。结果观察组和对照组血清淀粉样蛋白A水平分别为(95.56±52.00) mg/L和(15.28±5.49) mg/L,差异有统计学意义(t=13.73,P<0.01);随着慢性阻塞性肺疾病急性加重期发作程度加重,血清淀粉样蛋白A水平显著升高,差异有统计学意义(F=245.83,P<0.01);血清淀粉样蛋白A水平和慢性阻塞性肺疾病发作程度呈正相关(r=0.57,P<0.01)。结论血清淀粉样蛋白A水平可早期用于评估慢性阻塞性肺疾病急性加重期严重程度。
Objective To observe the changes in serum amyloid A level and its clinical significance in acute exacerbation of chronic obstructive pulmonary disease. Methods Eighty patients with acute exacerbation of chronic obstructive pulmonary disease were selected as the observation group, who were hospitalized from September 2016 to September 2017, and 80 patients for physical examination at the same period were selected as the control group. The levels of serum amyloid A was detected in both groups. And the levels of serum amyloid A were compared in different degree of patients with acute exacerbation of chronic obstructive pulmonary disease. Results The levels of serum amyloid A in the observation group and the control group were(95.56±52.00) mg/L and(15.28±5.49) mg/L respectively, and the difference between them was statistically significant(t=13.73, P<0.01). With the exacerbation of acute exacerbation of chronic obstructive pulmonary disease, serum amyloid A levels increased significantly, with the differences statistically significant(F=245.83, P<0.01). The level of serum amyloid A was positively correlated with the onset of chronic obstructive pulmonary disease(r=0.57, P<0.01). Conclusion Serum amyloid A levels can be used early to assess the severity of acute exacerbation of chronic obstructive pulmonary disease.
Objective To observe the changes in serum amyloid A level and its clinical significance in acute exacerbation of chronic obstructive pulmonary disease. Methods Eighty patients with acute exacerbation of chronic obstructive pulmonary disease were selected as the observation group, who were hospitalized from September 2016 to September 2017, and 80 patients for physical examination at the same period were selected as the control group. The levels of serum amyloid A was detected in both groups. And the levels of serum amyloid A were compared in different degree of patients with acute exacerbation of chronic obstructive pulmonary disease. Results The levels of serum amyloid A in the observation group and the control group were(95.56±52.00) mg/L and(15.28±5.49) mg/L respectively, and the difference between them was statistically significant(t=13.73, P<0.01). With the exacerbation of acute exacerbation of chronic obstructive pulmonary disease, serum amyloid A levels increased significantly, with the differences statistically significant(F=245.83, P<0.01). The level of serum amyloid A was positively correlated with the onset of chronic obstructive pulmonary disease(r=0.57, P<0.01). Conclusion Serum amyloid A levels can be used early to assess the severity of acute exacerbation of chronic obstructive pulmonary disease.
引文
[1] 王飞,周苑频,夏建军,等.吸烟与慢性阻塞性肺疾病患者肺部结构改变的相关性[J].临床肺科杂志,2018,23(1):17-20.
[2] 姚文飞,屠春林,赵开顺,等.慢性阻塞性肺疾病的肺康复研究进展[J].临床肺科杂志,2017,22(2):347-350.
[3] 罗文婷,林艺兰.厦门市慢性阻塞性肺疾病死亡趋势分析及预测[J].疾病监测与控制,2016,10(10):783-785.
[4] 王勇,陈江,陈兆俊.COPD评估测试在慢性阻塞性肺疾病临床评价中的意义[J].浙江实用医学,2017,22(5):332-354..
[5] 钟国泽.不同病原体致COPD患者急性加重期血清炎症标志物改变及对患者临床转归的影响[J].中国微生态学杂志,2018,30(4):456-460.
[6] 徐磊.降钙素原、血清淀粉样蛋白A、肺表面活性蛋白和IL-6在重症肺炎的检测意义[J].标记免疫分析与临床,2017,24(8):911-913.
[7] 华雯,黄华琼,沈华浩.《支气管哮喘防治指南(2016年版)》解读[J].浙江大学学报:医学版,2016,45(5):447-452.
[8] 庞红燕,杨汀,王辰.2016年更新版GOLD慢性阻塞性肺疾病诊断、治疗和预防的全球策略简介[J].中国医学前沿杂志:电子版,2016,8(7):28-32..
[9] 吕燕,李家珍,张立宏,等.健身气功八段锦对慢性阻塞性肺疾病患者生活质量及住院满意度的影响[J].中国医药导报,2015,12(30):161-164..
[10] 马千里,王长征.深入认识慢性阻塞性肺疾病的急性加重[J].中国呼吸与危重监护杂志,2016,15(3):213-215.
[11] 李海玲,李凡.GOLD 2017更新要点解读及其对中国慢性阻塞性肺疾病分级诊疗的启示[J].中国全科医学,2017,20(18):2171-2175.
[12] 吴海燕,钱钧,李树雯,等心肺康复运动训练对COPD稳定期患者肺功能的影响[J].中国康复医学杂志,2016,31(3):351-353.
[13] 刘亚男,许文兵,孟淑珍,等.探究峰流速仪呼气峰流速检测对慢性阻塞性肺疾病的筛查效力[J].中国呼吸与危重监护杂志,2015,14(3):250-254.
[14] 胡彦峰,祁秀峰,毛哲哲,等.降钙素原与慢性阻塞性肺疾病急性加重期关系的研究进展[J].三峡大学学报:自然科学版,2017,39(S1):21-23.
[15] 丁艳荣,侯晓军.血常规、CRP和PCT在一般人群感染性疾病早期诊断中的临床价值[J].临床医学研究与实践,2018,3(12):148-149.
[16] 郑卫国,程南,张晶,等.全麻联合硬膜外麻醉对腹腔镜胆囊切除术患者肺部感染及应激反应的影响[J].中华医院感染学杂志,2018(10):1522-1562.
[17] 唐芳,张波,沈俊.维持性血液透析对患者血清降钙素原、白细胞介素-6及超敏C反应蛋白的影响[J].贵州医科大学学报,2018(4):478-481.
[18] 耿利娇,张起顺,赵俊,等.降钙素原与血清和肽素及C-反应蛋白联合检测在脑出血肺部感染患者早期诊断中的价值和意义[J].中华医院感染学杂志,2018(10):1489-1499.
[19] 杨学,冯喜英,张嫚,等.血清淀粉样蛋白A与呼吸系统疾病的研究进展[J].临床肺科杂志,2014,19(8):1502-1504.
[20] 晏文芬,汤敏娟,冼洁能.探讨降钙素原、超敏C-反应蛋白和血清淀粉样蛋白A在老年慢性阻塞性肺疾病急性加重期中的表达及其临床意义[J].中国医学工程,2016,24(7):34-36.
[2] 姚文飞,屠春林,赵开顺,等.慢性阻塞性肺疾病的肺康复研究进展[J].临床肺科杂志,2017,22(2):347-350.
[3] 罗文婷,林艺兰.厦门市慢性阻塞性肺疾病死亡趋势分析及预测[J].疾病监测与控制,2016,10(10):783-785.
[4] 王勇,陈江,陈兆俊.COPD评估测试在慢性阻塞性肺疾病临床评价中的意义[J].浙江实用医学,2017,22(5):332-354..
[5] 钟国泽.不同病原体致COPD患者急性加重期血清炎症标志物改变及对患者临床转归的影响[J].中国微生态学杂志,2018,30(4):456-460.
[6] 徐磊.降钙素原、血清淀粉样蛋白A、肺表面活性蛋白和IL-6在重症肺炎的检测意义[J].标记免疫分析与临床,2017,24(8):911-913.
[7] 华雯,黄华琼,沈华浩.《支气管哮喘防治指南(2016年版)》解读[J].浙江大学学报:医学版,2016,45(5):447-452.
[8] 庞红燕,杨汀,王辰.2016年更新版GOLD慢性阻塞性肺疾病诊断、治疗和预防的全球策略简介[J].中国医学前沿杂志:电子版,2016,8(7):28-32..
[9] 吕燕,李家珍,张立宏,等.健身气功八段锦对慢性阻塞性肺疾病患者生活质量及住院满意度的影响[J].中国医药导报,2015,12(30):161-164..
[10] 马千里,王长征.深入认识慢性阻塞性肺疾病的急性加重[J].中国呼吸与危重监护杂志,2016,15(3):213-215.
[11] 李海玲,李凡.GOLD 2017更新要点解读及其对中国慢性阻塞性肺疾病分级诊疗的启示[J].中国全科医学,2017,20(18):2171-2175.
[12] 吴海燕,钱钧,李树雯,等心肺康复运动训练对COPD稳定期患者肺功能的影响[J].中国康复医学杂志,2016,31(3):351-353.
[13] 刘亚男,许文兵,孟淑珍,等.探究峰流速仪呼气峰流速检测对慢性阻塞性肺疾病的筛查效力[J].中国呼吸与危重监护杂志,2015,14(3):250-254.
[14] 胡彦峰,祁秀峰,毛哲哲,等.降钙素原与慢性阻塞性肺疾病急性加重期关系的研究进展[J].三峡大学学报:自然科学版,2017,39(S1):21-23.
[15] 丁艳荣,侯晓军.血常规、CRP和PCT在一般人群感染性疾病早期诊断中的临床价值[J].临床医学研究与实践,2018,3(12):148-149.
[16] 郑卫国,程南,张晶,等.全麻联合硬膜外麻醉对腹腔镜胆囊切除术患者肺部感染及应激反应的影响[J].中华医院感染学杂志,2018(10):1522-1562.
[17] 唐芳,张波,沈俊.维持性血液透析对患者血清降钙素原、白细胞介素-6及超敏C反应蛋白的影响[J].贵州医科大学学报,2018(4):478-481.
[18] 耿利娇,张起顺,赵俊,等.降钙素原与血清和肽素及C-反应蛋白联合检测在脑出血肺部感染患者早期诊断中的价值和意义[J].中华医院感染学杂志,2018(10):1489-1499.
[19] 杨学,冯喜英,张嫚,等.血清淀粉样蛋白A与呼吸系统疾病的研究进展[J].临床肺科杂志,2014,19(8):1502-1504.
[20] 晏文芬,汤敏娟,冼洁能.探讨降钙素原、超敏C-反应蛋白和血清淀粉样蛋白A在老年慢性阻塞性肺疾病急性加重期中的表达及其临床意义[J].中国医学工程,2016,24(7):34-36.